# Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma

> **NCT04453826** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 388 (estimated)

## Conditions studied

- Nasopharyngeal Cancer
- Chemotherapy
- Radiotherapy
- PD-1 Therapy

## Interventions

- **DRUG:** Camrelizumab plus chemo-radiotherapy
- **DRUG:** Chemo-radiotherapy alone

## Key facts

- **NCT ID:** NCT04453826
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-01
- **Primary completion:** 2026-09
- **Final completion:** 2028-09
- **Target enrollment:** 388 (ESTIMATED)
- **Last updated:** 2020-09-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04453826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04453826, "Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04453826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*